Fortress Biotech regains Nasdaq compliance; Sentynl takes over CUTX-101 development

Fortress Biotech, Inc.

Nasdaq notified Fortress on Oct 24, 2023 of compliance with $1.00 bid price requirement; listing matter closed.
Sentynl elected Approval Deadline Transfer for CUTX-101 after NDA not approved by Sep 30, 2023; closing expected Nov 2023.
Cyprium retains up to $133.5M in milestones, tiered royalties (3%–12.5%), and any priority review voucher.
Transfer expected to reduce Cyprium's development spending on CUTX-101.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.